Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MPER-656 Liposome Vaccine in Healthy Adults
NCT03934541Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2019
- Primary completion
- Feb 2021
- Modality
- Vaccines & Immunotherapeutics, Targeted Liposomes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MPER-656 in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Pain and/or Tenderness, Number of Participants Reporting Local Reactogenicity Signs and Symptoms: Erythema and/or Induration and 9 more. Started Aug 2019; status: completed.
02
Drugs
MPER-656
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03934541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03934541.